ImmunityBio Inc (IBRX)
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
📈 **POSITIVE** • Medium confidence analysis (73%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business